• Je něco špatně v tomto záznamu ?

Glycogen as an advantageous polymer carrier in cancer theranostics: Straightforward in vivo evidence

A. Gálisová, M. Jirátová, M. Rabyk, E. Sticová, M. Hájek, M. Hrubý, D. Jirák,

. 2020 ; 10 (1) : 10411. [pub] 20200626

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028080

As a natural polysaccharide polymer, glycogen possesses suitable properties for use as a nanoparticle carrier in cancer theranostics. Not only it is inherently biocompatible, it can also be easily chemically modified with various moieties. Synthetic glycogen conjugates can passively accumulate in tumours due to enhanced permeability of tumour vessels and limited lymphatic drainage (the EPR effect). For this study, we developed and examined a glycogen-based carrier containing a gadolinium chelate and near-infrared fluorescent dye. Our aim was to monitor biodistribution and accumulation in tumour-bearing rats using magnetic resonance and fluorescence imaging. Our data clearly show that these conjugates possess suitable imaging and tumour-targeting properties, and are safe under both in vitro and in vivo conditions. Additional modification of glycogen polymers with poly(2-alkyl-2-oxazolines) led to a reduction in the elimination rate and lower uptake in internal organs (lower whole-body background: 45% and 27% lower MRI signals of oxazoline-based conjugates in the liver and kidneys, respectively compared to the unmodified version). Our results highlight the potential of multimodal glycogen-based nanopolymers as a carrier for drug delivery systems in tumour diagnosis and treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028080
003      
CZ-PrNML
005      
20210114152933.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-020-67277-y $2 doi
035    __
$a (PubMed)32591567
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Gálisová, Andrea $u MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
245    10
$a Glycogen as an advantageous polymer carrier in cancer theranostics: Straightforward in vivo evidence / $c A. Gálisová, M. Jirátová, M. Rabyk, E. Sticová, M. Hájek, M. Hrubý, D. Jirák,
520    9_
$a As a natural polysaccharide polymer, glycogen possesses suitable properties for use as a nanoparticle carrier in cancer theranostics. Not only it is inherently biocompatible, it can also be easily chemically modified with various moieties. Synthetic glycogen conjugates can passively accumulate in tumours due to enhanced permeability of tumour vessels and limited lymphatic drainage (the EPR effect). For this study, we developed and examined a glycogen-based carrier containing a gadolinium chelate and near-infrared fluorescent dye. Our aim was to monitor biodistribution and accumulation in tumour-bearing rats using magnetic resonance and fluorescence imaging. Our data clearly show that these conjugates possess suitable imaging and tumour-targeting properties, and are safe under both in vitro and in vivo conditions. Additional modification of glycogen polymers with poly(2-alkyl-2-oxazolines) led to a reduction in the elimination rate and lower uptake in internal organs (lower whole-body background: 45% and 27% lower MRI signals of oxazoline-based conjugates in the liver and kidneys, respectively compared to the unmodified version). Our results highlight the potential of multimodal glycogen-based nanopolymers as a carrier for drug delivery systems in tumour diagnosis and treatment.
650    _2
$a zvířata $7 D000818
650    _2
$a antitumorózní látky $x aplikace a dávkování $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a systémy cílené aplikace léků $7 D016503
650    _2
$a glykogen $x aplikace a dávkování $7 D006003
650    _2
$a nádory $x farmakoterapie $7 D009369
650    _2
$a krysa rodu Rattus $7 D051381
650    12
$a teranostická nanomedicína $7 D000068936
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jirátová, Markéta $u MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Physiology, Faculty of Science, Charles University, Prague, Czech Republic.
700    1_
$a Rabyk, Mariia $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Sticová, Eva $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Hájek, Milan $u MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Hrubý, Martin $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Jirák, Daniel $u MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. daniel.jirak@ikem.cz. Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. daniel.jirak@ikem.cz. Department of Science and Research, Faculty of Health Studies, Technical University of Liberec, Liberec, Czech Republic. daniel.jirak@ikem.cz.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 10411
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32591567 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152931 $b ABA008
999    __
$a ok $b bmc $g 1608415 $s 1119260
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 10 $c 1 $d 10411 $e 20200626 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

    Možnosti archivace